IDEXX Laboratories Inc. (IDXX)
NASDAQ: IDXXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
IDXX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $40.43B
- P/E (TTM)
- 36.06
- Forward P/E
- 30.66
- EPS (TTM)
- $14.23
- Dividend yield
- None
- 52-week range
- 500.61 – 769.98
- Day range
- 506.29 – 514.51
- Volume / Avg
- 692.16K / 553.95K
- Beta
- —
- Shares outstanding
- 78.78M
- Next earnings
- Nov 2, 2026
52-week range
IDXX stock today
Shares of IDEXX Laboratories (IDXX) finished higher on Oct 8 at $513.14, a gain of 1.28% or $6.47 per share, versus the S&P 500's 0.47% decline. Shares are 33.4% below their 52-week high of $769.98, set on Nov 26, 2025 and 2.5% above the 52-week low of $500.61, near the bottom of the past year's range. IDXX is down 24.2% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has lost 18.5%.
IDEXX Laboratories trades at 36.1x its trailing twelve-month earnings per share of $14.23. Its forward P/E of 30.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. IDEXX Laboratories's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About IDEXX Laboratories
Company profileIDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Michael G. Erickson Ph.D.
- Headquarters
- Westbrook, ME
- Employees
- 11,000
- IPO year
- 1991
- Website
- idexx.com
Financial highlights
Full financialsIn fiscal 2025, IDEXX Laboratories generated $4.30 billion in revenue, up 10.4% from fiscal 2024, its 17th consecutive year of revenue growth. Net income was $1.06 billion (+19.3% year over year), for a net margin of 24.6% versus a median of 22.8% in the prior 5 years. Gross margin was 61.8% (up from 61.0%) and operating margin 31.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $4.30B | $3.90B | $3.66B | $3.37B | $3.22B |
| Growth | +10.42% | +6.46% | +8.72% | +4.73% | +18.79% |
| Net income | $1.06B | $887.87M | $845.04M | $679.09M | $744.85M |
| EPS (diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
Analyst forecast
ForecastConsensus (13 analysts)
buy
Avg. price target
$701.33+36.67%
- Strong buy 4
- Buy 4
- Hold 4
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $3.70
- Last reported (Q2 2026)
- Aug 4, 2026
- EPS actual vs est.
- $4.27 vs —
IDXX news
All IDXX news- Should You Continue to Hold IDXX Stock in Your Portfolio?NasdaqIDXX, TFX, GMED, VCYT
- IDEXX Laboratories Highlights Diagnostic Pipeline, Reaffirms Long-Term Growth TargetsNasdaq
- IDEXX Highlights Diagnostics Growth Drivers, Cancer Testing at Morgan Stanley ConferenceNasdaqIDXX, MS
- 10 large and mega-cap U.S. healthcare stocks with the weakest momentum gradesSeeking Alpha
- IDEXX Stock Gains Following the Acquisition of CoVetNasdaqIDXX, TFX, GMED, VCYT
- IDEXX Buys CoVetAI To Expand Veterinary Workflow IntelligenceNasdaq
- IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaIDXX, MS
- Insider Alert: IDEXX Director Lawrence Kingsley Sells $1.2 Million of StockNasdaq
IDEXX Laboratories peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LNTHLantheus Holdings Inc. | 100.12 | -0.06% | $6.54B | vs IDXX |
| ORKAOruka Therapeutics Inc. | 77.28 | -2.79% | $5.12B | vs IDXX |
| NEOGNeogen Corporation | 11.71 | +0.26% | $2.55B | vs IDXX |
| CLDXCelldex Therapeutics Inc. | 29.30 | -3.71% | $2.30B | vs IDXX |
| NTLAIntellia Therapeutics Inc. | 12.60 | +7.60% | $1.77B | vs IDXX |
| QDELQuidelOrtho Corporation | 12.41 | +0.81% | $851.02M | vs IDXX |
| ACHVAchieve Life Sciences Inc. | 7.19 | -0.69% | $741.31M | vs IDXX |
| MYGNMyriad Genetics Inc. | 4.20 | -1.87% | $401.73M | vs IDXX |
Indexes, lists and sector
Index membership
IDEXX Laboratories stock FAQ
What is IDEXX Laboratories's stock price today?
IDXX last traded at $513.14 as of Oct 8, 4:00 PM EDT, up 1.28% on the day. Prices are delayed at least 15 minutes.
Does IDEXX Laboratories pay a dividend?
No. IDEXX Laboratories does not currently pay a regular cash dividend.
When is IDEXX Laboratories's next earnings date?
IDEXX Laboratories is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $3.70.
What is IDXX's P/E ratio?
IDXX trades at a trailing P/E ratio of 36.06 and a forward P/E of 30.66.
Is IDEXX Laboratories in the S&P 500?
Yes. IDEXX Laboratories (IDXX) is a constituent of the S&P 500 index.
Who is IDEXX Laboratories's CEO?
Mr. Michael G. Erickson Ph.D. is the chief executive officer of IDEXX Laboratories Inc., which has about 11,000 employees.
Has IDXX ever split its stock?
Yes. The most recent IDXX stock split was a 2-for-1 split on Jun 16, 2015, one of 4 splits on record.